To Compare the Efficacy of Two Ayurvedic Drugs in the management of Pain during Menstruation

An Open-Label, Double-Arm, Randomized Clinical Trial To Study The Efficacy Of Chitraka Granthikadi Ghana Vati And Sapthasara Ghana Vati In Udavatini Yonivyapad (Pimary Dysmenorrhoea) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106200

Enrollment

Registered

2026-03-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects fulfilling the Diagnostic criteria 2. Age between 16-35 years 3. Regular menstrual cycle 4. Willing to sign the informed written consent form.(Guardian consent if age less than 18 years)

Exclusion criteria

Exclusion criteria: 1. Known cases of HIV, HBsAg, VDRL 2. Subjects with IUCD 3. Secondary dysmenorrhoea 4. Known cases of Diabetes and Hypertensive disorders, Cardiac disorders

Design outcomes

Primary

Measure	Time frame
1.Reduction in pain intensity during menstruation. [As assessed by WaLLID Scores before and after treatment.] Timepoint: 90 Days	—

Secondary

Measure	Time frame
1. Duration of pain relief during the treatment and post-treatment cycles. 2. Reduction in associated symptoms (e.g., nausea, headache, backache, fatigue, mood disturbances). 3. Improvement in quality of life, assessed using a validated Menstrual Distress Questionnaire (MDQ) or similar tool. 4. Changes in the pattern of menstruation, if any (flow, duration, regularity). 5. Patient s overall satisfaction with the treatment (using a Likert scale or Global Assessment Score). 6. Safety and tolerability of the drug based on reported adverse events or lab parameters if used. Timepoint: 90 Days	—

Measure

Time frame

1. Duration of pain relief during the treatment and post-treatment cycles. 2. Reduction in associated symptoms (e.g., nausea, headache, backache, fatigue, mood disturbances). 3. Improvement in quality of life, assessed using a validated Menstrual Distress Questionnaire (MDQ) or similar tool. 4. Changes in the pattern of menstruation, if any (flow, duration, regularity). 5. Patient s overall satisfaction with the treatment (using a Likert scale or Global Assessment Score). 6. Safety and tolerability of the drug based on reported adverse events or lab parameters if used. Timepoint: 90 Days

—

Countries

India

Contacts

Public ContactTaruna Kaushik

Sri Dharmasthala Manjunatheshwara College Of Ayurveda and Hospital

drmadhuayu@sdmcahhassan.org8970167939

Outcome results